Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bodybuilding Health+ vs Invigor Medical

Bodybuilding Health+
Graded #33

Lower grade

vs+8
Invigor Medical
Graded #13

Higher grade

The verdict

Invigor Medical takes it — 86.1/100 to 78.1/100.

Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established pharmacy operator with steady mid-market pricing and a broad catalog.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBodybuilding Health+ +4
88
84
Dose & formulationEven
84
84
Clinical oversightInvigor Medical +14
74
88
Labs & monitoringInvigor Medical +18
68
86
FulfillmentInvigor Medical +10
78
88
Contract termsInvigor Medical +28
62
90
Bodybuilding Health+ · left barInvigor Medical · right bar

The numbers

MetricBodybuilding Health+Invigor Medical
WeighScore78.1/10086.1/100
GradeC+B
Scorecard rank#33#13
Semaglutide$179/mo month-to-month (3/6/12-month prepay: $159/$149/$139 per month)$199/mo
Tirzepatide$209/mo month-to-month (3/6/12-month prepay costs more, not less: $286/$250/$244 per month)$339/mo
CoverageNot disclosedNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Bodybuilding Health+

Graded #33 · C+

Strengths

  • Both ladders are published before the intake — semaglutide $179/mo month-to-month, genuinely stepping down to $139/mo on the 12-month prepay; tirzepatide $209/mo month-to-month
  • Licensed brand extension of Bodybuilding.com (trademark relationship stated on-site), which lends familiarity vs. anonymous GLP-1 startups
  • Unusually broad menu under one login — GLP-1 plus NAD+ (injection or nasal), sermorelin (injection or sublingual ODT), ED/tadalafil, and a deep peptide catalog
  • Standard telehealth flow with clear FDA/compounding disclaimers — online intake reviewed by independent licensed providers, U.S. compounding-pharmacy fulfillment, free until a provider approves

Where it loses points

  • Its tirzepatide bundles cost MORE per month than paying monthly — $286 at three months, $250 at six, $244 at twelve, against $209 month-to-month — while all three are badged as savings and the 12-month one as "Best Value · Save $586" against a $2,922 bill vs $2,508. Only the semaglutide ladder actually descends
  • Compounded and not FDA-approved — not Wegovy/Ozempic or Zepbound/Mounjaro; the site itself states these have not been evaluated by the FDA for safety, effectiveness, or quality
  • Brand-new operator — Dynamo Group LLC launched the storefront around April 2026 with only a thin, mixed ~26-review Trustpilot record (cancellation and billing complaints)
  • All sales final — prescription products are non-returnable, the medical-consult fee is non-refundable, and there are no refunds for dissatisfaction or results
  • Pharmacy and provider network aren't named on the live consumer pages, no LegitScript seal we could verify on-site, and the catalog reaches into investigational Retatrutide and research-grade peptides
Invigor Medical

Graded #13 · B

Strengths

  • Mid-market pricing on both molecules
  • Long-running operator

Where it loses points

  • No explicit states list
  • Compounded only

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard